Longevity & AgingPress Release

Shorter Antibiotic Courses May Bridge the Gap to Biologics in HS

An expert explains why antibiotics still matter in hidradenitis suppurativa—and why shorter courses and inflammation control are taking priority.

Thursday, November 12, 2026 0 views
Published in MedPage Today
Article visualization: Shorter Antibiotic Courses May Bridge the Gap to Biologics in HS

Summary

Hidradenitis suppurativa, a chronic inflammatory skin disease, is increasingly treated by targeting inflammation rather than presumed infection. In a MedPage Today interview, dermatologist Megan Rogge explains that antibiotics still have a role, but often as temporary support rather than the main treatment. Doxycycline and minocycline can help reduce inflammation, while antibiotics may also bridge the waiting period before biologic drugs take effect. She describes clindamycin plus rifampin as a treatment studied over 10 to 12 weeks and ertapenem as a short rescue treatment. The goal is to control symptoms without unnecessary prolonged exposure that can encourage antibiotic resistance. These comments reflect expert clinical perspective, not new trial findings. Patients should discuss the purpose and planned duration of antibiotics with their dermatologist rather than change treatment themselves.

0:00--:--

Detailed Summary

Hidradenitis suppurativa is a chronic inflammatory skin disease that causes painful lumps and recurring lesions. As targeted treatments expand, clinicians are reconsidering how antibiotics fit into care. In a MedPage Today interview from a European dermatology meeting, dermatologist Megan Rogge describes a shift toward shorter antibiotic courses and treatments that address inflammation rather than presumed infection.

Rogge explains that HS should not primarily be treated as an infection. Bacteria and the skin microbiome can influence disease, but she notes that many lesions are sterile. Antibiotics such as doxycycline and minocycline may still help because they reduce inflammation, not simply because they kill bacteria. This distinction helps explain their continuing role despite newer options.

For moderate disease, Rogge describes moving toward biologic drugs rather than relying on antibiotics alone. Antibiotics may serve as a temporary bridge while a biologic begins working. She identifies clindamycin plus rifampin as a combination studied for courses lasting 10 to 12 weeks. Ertapenem, another antibiotic, is described as a rescue treatment with a short, clearly defined course.

The practical message is to give every antibiotic prescription a clear purpose and planned duration. Patients can ask whether treatment is intended to reduce inflammation, manage infection, or provide temporary relief while another therapy takes effect. Limiting prolonged exposure may reduce the risk of resistant bacteria. Decisions about starting, stopping, or changing treatment should remain individualized and supervised by a clinician familiar with HS care.

This report presents expert commentary, not a new clinical trial or a systematic comparison of treatments. It provides no patient numbers, response rates, or direct evidence that shorter courses outperform longer ones. The stated durations should not be treated as universal instructions. Current guidelines and primary studies are needed to confirm appropriate regimens, safety considerations, and which patients are most likely to benefit substantially.

Key Findings

  • Doxycycline and minocycline may help HS through anti-inflammatory effects, not only their ability to kill bacteria.
  • For moderate HS, Rogge describes prioritizing biologic therapy rather than relying on antibiotics alone.
  • Antibiotics can provide temporary bridge treatment while biologic drugs begin working.
  • Clindamycin plus rifampin has been studied over 10 to 12 weeks; ertapenem is described as short-course rescue treatment.
  • Ask your dermatologist about each antibiotic’s purpose and planned duration; avoid changing treatment without clinical guidance.

Methodology

This is a medical meeting news report presenting a dermatologist’s video interview, published by MedPage Today. Its evidence basis is expert clinical commentary with references to studied treatments, not newly reported trial data or a systematic evidence review.

Study Limitations

The report provides no study citations, treatment response rates, patient characteristics, or comparative safety data. Primary studies and current guidelines should be checked before applying the stated durations or choosing between antibiotics and biologics.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.

Enter your email to subscribe: